Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25629532 | 0.93 | OTC (0.49) | OTCFOLH1SMN1; SMN2ALDH1A1ALB | |
| SCHEMBL10000704 | 0.93 | OTC (0.49) | OTCFOLH1SMN1; SMN2ALDH1A1ALB | |
| SCHEMBL9728848 | 0.92 | OTC (0.48) | OTCFOLH1SMN1; SMN2ALDH1A1NOD1 | |
| SCHEMBL10000705 | 0.91 | SIGMAR1 (0.45) | SIGMAR1OTCSMN1; SMN2ALDH1A1 | |
| SCHEMBL16089032 | 0.87 | FOLH1 (0.42) | SIGMAR1OTCFOLH1SMN1; SMN2TP53 | |
| SCHEMBL31429756 | 0.85 | FOLH1 (0.43) | SIGMAR1OTCFOLH1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20614501 | 0.85 | FOLH1 (0.43) | SIGMAR1OTCFOLH1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27323887 | 0.85 | FOLH1 (0.43) | SIGMAR1OTCFOLH1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17246791 | 0.83 | FOLH1 (0.53) | FOLH1NOD1ALB | |
| SCHEMBL25629482 | 0.83 | OTC (0.43) | OTCFOLH1SMN1; SMN2ALDH1A1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | SNU R&DB FOUNDATION (KR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029177-A1 | HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF | DDC, AAAS, DNPEP | SIGMAR1 1198/4885OTC 2095/4885FOLH1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.